debut fund
Beyond Market Intelligence keeps debut fund in one place: 2 stories so far. The section currently leads with “Proximal Ventures Invests $27.5 Million in AI for Drug Development” and “Evertrue Capital backs European AI and fintech with a $17M debut fund”. Sahir Raoof just raised $27.5 million for Proximal Ventures, a new fund targeting AI-driven drug development. Evertrue Capital is putting $17 million behind a simple idea: early-stage AI and fintech in Europe deserve focused backing. Acme AI is the next-generation, AI-powered spreadsheet platform built to replace Excel and redefine how analysts, data scientists, and enterprise teams work… The list below is every debut fund story on Beyond Market Intelligence, newest first.
Proximal Ventures Invests $27.5 Million in AI for Drug Development
Sahir Raoof just raised $27.5 million for Proximal Ventures, a new fund targeting AI-driven drug development. That capital signals serious confidence in applying modern AI to the slow, expensive work of discovering new therapies. Legacy approaches to pharmaceutical R&D are overdue for an upgrade. For readers who want to see how AI can simplify complex data, our piece on Usul's approach to neural networks offers a practical look under the hood.
Evertrue Capital backs European AI and fintech with a $17M debut fund
Evertrue Capital is putting $17 million behind a simple idea: early-stage AI and fintech in Europe deserve focused backing. That debut fund signals confidence in founders building the next generation of data-driven tools. We see a clear through-line here. Our piece on "Building a Bounded Canvas for AI Agents with Proven Engineering Principles" explores how thoughtful architecture gives those same founders room to innovate without chaos. Evertrue's bet suggests that discipline and ambition can go hand in hand.